New Neurotoxins on the Horizon

Aesthetic Surgery Journal

Volumn 28, Issue 3, 2008, Pages 325-330

  Freeman, Scott R ^a   Cohen, Joel L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; BOTULINUM TOXIN F; BOTULINUM TOXIN G; NEUROTOXIN; NT 201; PROSIGNE; PURTOX; RELOXIN;

ARTICLE; BACTERIAL STRAIN; BLEPHAROSPASM; CERVICAL DYSTONIA; CLINICAL TRIAL; CLOSTRIDIUM; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DYSTONIA; ESTHETIC SURGERY; FOOD AND DRUG ADMINISTRATION; GRAM POSITIVE BACTERIUM; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; INJECTION SITE REACTION; MOLECULAR WEIGHT; MOTOR DYSFUNCTION; PRIORITY JOURNAL; PTOSIS; STRABISMUS; UNITED STATES;

ADMINISTRATION, TOPICAL; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; COSMETIC TECHNIQUES; HUMANS; HYPERHIDROSIS; NEUROTOXINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 43949093074     PISSN: 1090820X     EISSN: 1527330X     Source Type: Journal    
DOI: 10.1016/j.asj.2008.03.006     Document Type: Article

References (58)

1. Flynn T. Update on botulinum toxin. Semin Cutan Med Surg 25 (2006) 115-121
2. American Society for Aesthetic Plastic Surgery. Cosmetic Surgery National Data Bank Statistics, 2007. Available at: http://www.surgery.org/download/2007stats.pdf Accessed March 13, 2007.
3. Huang W., Foster J., and Rogachefsky A. Pharmacology of botulinum toxin. J Am Acad Dermatol 43 2 Pt 1 (2000) 249-259
4. Ting P., and Freiman A. The story of Clostridium botulinum From food poisoning to BOTOX. Clin Med 4 (2004) 258-261
5. Flynn T. Myobloc. Dermatol Clin 22 (2004) 207-211
6. World Intellectual Property Organization. Available at: http://www.wipo.int/pctdb/en/wo.jsp?IA5WO2007041664&WO52007041664 &DISPLAY5DESC Accessed January 1, 2008.
7. Sadick N., and Matarasso S. Comparison of botulinum toxins A and B in the treatment of facial rhytides. Dermatol Clin 22 (2004) 221-226
8. Cote T., Mohan A., Polder J., Walton M., and Braun M. Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 53 (2005) 407-415
9. Matarasso S. Comparison of botulinum toxin types A and B: A bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 29 (2003) 7-13
10. Lowe N., Glaser D., Eadie N., Daggett S., Kowalski J., Lai P., and the North American BOTOX in Primary Axillary Hyperhidrosis Clinical Study Group. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: A 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol 56 (2007) 604-611
11. Lowe N., Maxwell A., and Harper H. Botulinum A exotoxin for glabellar folds: A double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol 35 (1996) 569-572
12. Lowe P., Patnaik R., and Lowe N. A comparison of two botulinum type a toxin preparations for the treatment of glabellar lines: Double-blind, randomized, pilot study. Dermatol Surg 31 (2005) 1651-1654
13. Lowe P., Patnaik R., and Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: A double-blind, randomized study. J Am Acad Dermatol 55 (2006) 975-980
14. Carruthers J., Lowe N., Menter M., Gibson J., Nordquist M., Mordaunt J., et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46 (2002) 840-849
15. Carruthers S., Fagien S., Matarasso S., and BOTOX Consensus Group. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg 114 6 Suppl (2004) 1S-22S
16. Carruthers J., and Carruthers A. Botulinum toxin type A treatment of multiple upper facial sites: Patient-reported outcomes. Dermatol Surg 33 1 Spec No. (2007) S10-S17
17. Hallett M. One man's poison-Clinical applications of botulinum toxin. N Engl J Med 341 (1999) 118-120
18. Fagien S., Cox S., Finn J., Werschler W., and Kowalski J. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: A double-blind, randomized, placebo-controlled study. Dermatol Surg 33 1 Spec No. (2007) S2-S9
19. Lizarralde M., Gutierrez S., and Venegas A. Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines. Dermatol Surg 33 (2007) 1328-1333
20. Hexsel D., De Almeida A., Rutowitsch M., De Castro I., Silveira V., Gobatto D., et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg 29 (2003) 523-529
21. Carruthers J., and Carruthers A. The evolution of botulinum neurotoxin type A for cosmetic applications. J Cosmet Laser Ther 9 (2007) 186-193
22. Ascher B., Zakine B., Kestemont P., Baspeyras M., Bougara A., and Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 51 (2004) 223-233
23. Monheit G., Carruthers A., Brandt F., and Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: Determination of optimal dose. Dermatol Surg 33 1 Spec No. (2007) S51-S59
24. Karsai S., Adrian R., Hammes S., Thimm J., and Raulin C. A randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity. Arch Dermatol 143 (2007) 1447-1449
25. Moreau M., Cauhepe C., Magues J., and Senard J. A double-blind, randomized, comparative study of Dysport vs. BOTOX in primary palmar hyperhidrosis. Br J Dermatol 149 (2003) 1041-1045
26. Talarico-Filho S., Mendonça D., Nascimento M., Sperandeo D., Macedo F., Sanctis D., et al. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg 33 1 Spec No. (2007) S44-S50
27. de Almeida A., Marques E., de Almeida J., Cunha T., and Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 33 1 Spec No. (2007) S37-S43
28. Ipsen Web site. Oncology research and development projects. Available at: http://www.ipsen.com/?page5researchdevelopment&content5projects Accessed November 13, 2007.
29. Rundle R. Botox faces worry lines in smooth skin game. Wall Street Journal (December 6, 2007) B1
30. Yablon S., Brashear A., Gordon M., Elovic E., Turkel C., Daggett S., et al. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: A pooled-data analysis of three clinical trials. Clin Ther 29 (2007) 683-690
31. Jankovic J., Vuong K., and Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60 (2003) 1186-1188
32. Lee S. Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. Dermatol Surg 33 1 Spec No. (2007) S105-S110
33. Rzany B., Dill-Muller D., Grablowitz D., Heckmann M., and Caird D. Repeated botulinum toxin A injections for the treatment of lines in the upper face: A retrospective study of 4,103 treatments in 945 patients. Dermatol Surg 33 1 Spec No. (2007) S18-S25
34. Wohlfarth K., Muller C., Sassin I., Comes G., and Grafe S. Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin Neuropharmacol 30 (2007) 86-94
35. Jost W., Blumel J., and Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 67 (2007) 669-683
36. Roggenkamper P., Jost W., Bihari K., Comes G., and Grafe S. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113 (2006) 303-312
37. Benecke R., Jost W., Kanovsky P., Ruzicka E., Comes G., and Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64 (2005) 1949-1951
38. Tang X., and Wan X. Comparison of Botox with a Chinese type A botulinum toxin. Chin Med J (Engl) 113 (2000) 794-798
39. Rieder C., Schestatsky P., Socal M., Monte T., Fricke D., Costa J., et al. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol 30 (2007) 39-42
40. Ramirez A., Reeck J., and Maas C. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg 126 (2002) 459-467
41. Lowe N., Yamauchi P., Lask G., Patnaik R., and Moore D. Botulinum toxins types A and B for brow furrows: Preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 4 (2002) 15-18
42. Sadick N. Botulinum toxin type B for glabellar wrinkles: A prospective open-label response study. Dermatol Surg 28 (2002) 817-821
43. Sadick N. Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2,400 and 3,000 U for the treatment of glabellar wrinkles. Dermatol Surg 29 (2003) 501-507
44. Baumann L., Stezinger A., Vujevich J., Halem M., Bryde J., Black L., et al. A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet: A double-blinded, placebo-controlled trial. Dermatol Surg 29 (2003) 508-515
45. Alster T., and Lupton J. Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A. Dermatol Surg 29 (2003) 516-518
46. Lew M., Brashear A., and Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: Summary of three controlled clinical trials. Neurology 55 12 Suppl 5 (2000) S29-S35
47. Flynn T., and Clark II R. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 29 (2003) 519-522
48. Glogau R. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: Results of a randomized, blinded, vehicle-controlled study. Dermatol Surg 33 1 Spec No. (2007) S76-S80
49. Heckmann M., Ceballos-Baumann A., and Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 344 (2001) 488-493
50. Beer K., and Waibel J. Botulinum toxin type A enhances the outcome of fractional resurfacing of the cheek. J Drugs Dermatol 6 (2007) 1151-1152
51. Kadunc B., Trindade D., Almeida A., Vanti A., and DI Chiacchio N. Botulinum toxin A adjunctive use in manual chemabrasion: Controlled long-term study for treatment of upper perioral vertical wrinkles. Dermatol Surg 33 (2007) 1066-1072
52. Mead R. Proud flesh: The cult of cosmetic surgery. The New Yorker (November 13, 2006)
53. American Society for Aesthetic Plastic Surgery. Cosmetic surgery national data bank statistics, 2007. Available at: http://www.surgery.org/download/2007stats.pdf Accessed March 13, 2008.
54. Bootleg Botox sentences. New York Times (January 27, 2006). Available at: http://query.nytimes.com/gst/fullpage.html?res59B02EFDB113FF934A15752C0A 9609C8B63 Accessed November 26, 2007.
55. Arnon S., Schechter R., Inglesby T., Henderson D., Bartlett J., Ascher M., et al. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 285 (2001) 1059-1070
56. Preliminary hearing resumes in fake botox case. Martha Vasqez accused in woman's death. Available at: http://www.theksbwchannel.com/news/9515118/detail.html Accessed December 31, 2007.
57. Bailly J. Medi-spas. Marie Claire (November, 2007) 77-80
58. Geraghty L. Saving face. More (December 2007/January 2008) 181-190